2OLlsen NJ,Stein CM.New drugs for rheumatoid arthritis[J].N Engl J Med,2004,350(21):2167-2179.
3Garrison L,Mcdonnell ND.Etanercept:therapeutic use in patients with rheumatoid arthritis[J].Ann Rheum Dis,1999,58(Suppl 1):65-69.
4Calabrese LH. Molecular differences in anticytokine therapies.Clin Exp Rheumatol,2003,21:241-248.
5Feldmann M,Brennan FM,Maini RN. Role of cytokines in rheumatoid arthritis.Annu Rev Immunol,1996,14:397-440.
6Butler DM,Maini RN,Feldmann M,et al.Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures:comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw,1995,6:225-230.
7Braun J,Sieper J.The sacroiliac joint in the spondyloarthropathies.Curr Opin Rheumatol,1996,8:275-297.
8Sandborn WJ,Hanauer SB.Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents,pharmacology,clinical results and safety.Inflamm Bowel Dis,1999,5:119-133.
9Brandt J,Haibel H,Comely D,et al.Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.Arthritis Rheum,2000,43:1346-1352.
10Brandt J,Haibel H,Sieper J,et al.Infliximab treatment of severe ankylosing spondylitis:one-year followup.Arthritis Rheum,2001,44:2936-2937.
